FDA concludes no causal link

The US Food and Drug Administration (FDA) has requested that manufacturers remove the boxed warning for suicidal behaviour and ideation from the labelling of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The decision follows an extensive review that began in 2023 after the European Medicines Agency (EMA) raised concerns about a potential signal of self-harm associated with GLP-1 medicines.

The FDA's review drew on data from clinical trials, post-marketing adverse event reports, and published observational studies. The agency concluded that the available evidence does not support a causal association between GLP-1 receptor agonist medicines and suicidal thoughts or actions.

Which medicines are affected

The boxed warning applied to FDA-approved GLP-1 receptor agonist products, including:

  • Semaglutide (Wegovy, Ozempic)
  • Liraglutide (Saxenda, Victoza)
  • Tirzepatide (Zepbound, Mounjaro) — a dual GLP-1/GIP agonist
  • Dulaglutide (Trulicity)
  • Exenatide (Byetta, Bydureon)

The removal applies to the labelling of these approved medicines. The research peptide market, which supplies non-pharmaceutical-grade GLP-1 agonists for research purposes, is not directly regulated under this labelling change, but the safety signal has been widely discussed in peptide research communities.

Context: the EMA investigation

The original concern was raised by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) in July 2023, following Icelandic reports of suicidal thoughts in patients using semaglutide and liraglutide. The PRAC conducted a review over several months, examining clinical trial data and post-marketing reports across the European Economic Area.

In April 2024, the EMA concluded that the available evidence did not support a causal association between GLP-1 receptor agonists and suicidal thoughts or actions. The FDA's recent decision to remove the boxed warning aligns with the EMA's earlier conclusion.

UK perspective: MHRA monitoring

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has been monitoring GLP-1 receptor agonist safety signals through the Yellow Card reporting system. The MHRA has not imposed a similar boxed warning, but has included suicidal ideation in the list of monitored adverse events for GLP-1 agonists.

Researchers using GLP-1 receptor agonist peptides in the UK should note that while the FDA and EMA have both concluded there is no causal link, pharmacovigilance monitoring continues. Adverse events observed during research should be reported through the appropriate channels.

Implications for peptide research

The removal of the boxed warning is reassuring for the GLP-1 receptor agonist research field, which has expanded rapidly with the development of multi-agonist peptides such as retatrutide (triple agonist), survodutide (dual GLP-1/glucagon), and CagriSema (amylin/GLP-1 combination). The safety profile of GLP-1 receptor agonists has been extensively studied, and the psychiatric safety signal — which caused significant concern in 2023 — now appears to have been a false alarm based on confounding and reporting bias.

However, researchers should continue to monitor psychiatric symptoms in study protocols, particularly for newer multi-agonist peptides where long-term safety data remain limited. The absence of a causal link does not mean these symptoms should be ignored — only that they are not caused by the drug class.

Bottom line

The FDA's decision to remove the boxed warning for suicidal ideation from GLP-1 receptor agonists resolves a safety concern that has hung over the GLP-1 peptide field since 2023. Both the FDA and EMA now agree there is no causal association. UK researchers should continue to follow MHRA guidance and report adverse events through the Yellow Card system.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.